Skip to main content

Military Health System

Test of Sitewide Banner

This is a test of the sitewide banner capability. In the case of an emergency, site visitors would be able to visit the news page for addition information.

Letter to the Editor: G6PD Deficiency in the Tafenoquine Era

Image of A funestus_James Gathany. This image shows a female Anopheles funestus mosquito that had landed on a human skin surface and was in the process of obtaining its blood meal. A. funestus is a known vector for the parasitic disease malaria. CDC/James Gathany

In the Dec. 2019 issue of the MSMR, Lee and Poitras reported a 2.2% prevalence of glucose-6-phosphate dehydrogenase (G6PD) deficiency among active duty U.S. service members between 2004 and 2018.1 Their study utilized Health Level 7-formatted chemistry data archived in the Composite Health Care System (CHCS), but it did not stratify by quantitative or qualitative testing.

When tafenoquine was approved by the U.S. Food and Drug Administration in 2018 for chemoprophylaxis and radical cure of Plasmodium vivax,2 the distinction between quantitative and qualitative testing became clinically significant. Formerly, primaquine was the only approved medication to treat hypnozoites, the dormant form of the parasite in the liver stage of malaria. Its use required a “normal” G6PD activity level, the threshold of which on qualitative tests was usually established at 30%–40%. Tafenoquine, with its longer half-life of 14 days (compared to 6 hours for primaquine), provides a far simpler dosing regimen for malaria chemoprophylaxis and radical cure, but it may precipitate hemolytic anemia at higher levels of G6PD activity. Consequently, the U.S. Centers for Disease Control and Prevention recommends a quantitative G6PD assessment before tafenoquine prescription2 to ensure activity exceeding 70%.3,4

An X-linked genetic disorder, G6PD deficiency in males is usually severe (enzyme activity < 30%), meaning that a “deficient” result on qualitative testing contraindicates the use of both primaquine and tafenoquine. The same is true for females who are homozygous or double heterozygous for mutant alleles—both of which are rare. However, single heterozygous females usually have milder deficiency (enzyme activity 30%–80%),3 meaning they would have a “normal” result on qualitative testing and could safely take primaquine but potentially not tafenoquine.

Univeral G6PD deficiency screening is required across the U.S. Armed Forces, but current policy does not mandate quantitative testing.5 Since tafenoquine may improve medication adherence and thus become a preferable antimalarial option, it is important to understand how many service members have only been qualitatively tested. In the U.S. Air Force, 167,945 active duty members had at least 1 G6PD test performed and recorded in the CHCS between 1 Jan. 2015 and 31 Dec. 2019. Of these, only 4,325 (2.6%), including 1,602 females, had a normal qualitative test with no quantitative result. This low percentage should continue to decrease since quantitative testing is standard protocol for all new recruits at U.S. Air Force basic military training as well as new officer accessions at the U.S. Air Force Academy and Officer Training School (email communication, Maj Dianne Frankel and Lt Col Kevin Baldovich, Dec. 2019 and Jan. 2020, respectively).

While the article by Lee and Poitras provides valuable information, G6PD deficiency surveillance in the tafenoquine era should incorporate quantitative values. These values should also be documented in service members’ deployment readiness records. For example, the Aeromedical Services Information Management System, the U.S. Air Force’s readiness platform, defines G6PD status as either “normal” or “deficient”—essentially as a qualitative test, even if a quantitative enzyme activity level is available in the electronic health record. This may lead to improper prescription of tafenoquine to airmen, particularly females, who are coded as having “normal” G6PD activity levels but whose levels are in fact intermediate.

Author affiliations: Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD (Maj Sayers; Lt Col Webber); Public Health and Preventive Medicine Department, U.S. Air Force School of Aerospace Medicine, Wright-Patterson Air Force Base, OH (Lt Col Webber).

Disclaimer: The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Air Force, the Department of Defense, or the U.S. Government.

References

  1. Lee J, Poitras BT. Prevalence of glucose-6-phosphate dehydrogenase deficiency, U.S. Armed Forces, May 2004–Sept. 2018. MSMR. 2019;26(12):14–17.
  2. Haston JC, Hwang J, Tan KR. Guidance for using tafenoquine for prevention and antirelapse therapy for malaria—United States, 2019. MMWR Morb Mortal Wkly Rep. 2019;68(46):1062–1068.
  3. Commons RJ, McCarthy JS, Price RN. Tafenoquine for the radical cure and prevention of malaria: the importance of testing for G6PD deficiency. Med J Aust. 2020;212(4):152–153.e1.
  4. Price RN, Commons RJ, Battle KE, Thriemer K, Mendis K. Plasmodium vivax in the era of the shrinking P. falciparum map. Trends Parasitol. 2020;36(6):560–570.
  5. Defense Health Agency, Department of Defense. Procedural Instruction 6025.14. Active Duty Service Members (ADSM) Erythrocyte Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency and Sickle Cell Trait (SCT) Screening. 6 Dec. 2018.

In reply:

We appreciate the response by Drs. Sayers and Webber to our article published in the Dec. 2019 issue of the MSMR on the prevalence of G6PD deficiency among active duty service members. We are in agreement that quantitative as well as qualitative testing for the genetic condition is imperative to prevent the potentially harmful side effects from the use of the 8-aminoquinoline (8-AQ) class of antimalarial drugs (tafenoquine and primaquine) for malaria chemoprophylaxis and radical cure. We applaud the Air Force for the implementation of quantitative screening of G6PD deficiency among new recruits.

Our article highlights the need for leadership awareness of G6PD deficiency diagnoses to reduce the possibility of adverse events from the use of the 8-AQ class of antimalarial drugs. The inclusion of quantitative G6PD testing is an important tool to further identify at-risk service members.

Respectfully,

MAJ Jangwoo Lee, PhD; Beth Poitras, MPH

You also may be interested in...

MSMR volume 30 issue 3 March 2023

Report
3/1/2023

March 2023 issue of MSMR, the Medical Surveillance Monthly Report

Letter to the Editor: Military Health System Exceeded Healthy People 2020 Goal for Rotavirus Vaccination

Article
3/1/2023
Logo800x480MSMR

Letter to the Editor commenting on November 2033 (volume 29 issue 11) MSMR Brief Report, "Pediatric Vaccine Completion and Compliance Among Infants Born to Active Duty Service Members, 2006-2016"

Notice to Readers: Vector-borne Disease Branch Detects Borrelia miyamotoi in Human Tick Submission

Article
3/1/2023
female Ixodes scapularis or deer tick

Notice of emerging tick-borne pathogen detected in January 2023 by the Vector-Borne Disease (VBD) Branch of the Defense Center Public Health-Aberdeen (DCPH-A)

Update: Malaria Among Members of the U.S. Armed Forces, 2013–2022

Article
3/1/2023
Mosquito trap

This article provides an annual update of rates and incident infections of malaria species among U.S. service members.

Medical Surveillance Monthly Report Volume 30 Number 2, February 2023

Report
2/1/2023

This issue of the peer-reviewed monthly journal published by the Armed Forces Health Surveillance Division (AFHSD) features the articles: Changing of the Guard: MSMR’s Second Editor-in-Chief Retires; Brief Report: Hospitalizations Among Active Duty Members of the U.S. Coast Guard, Fiscal Year 2021; Historical Perspective: The Critical Role of Disease and Non-Battle Injuries in Soldiers Isolated on Pacific Islands During the Second World War; From the Editor’s Desk.

Changing of the Guard: MSMR’s Second Editor-in-Chief Retires

Article
2/1/2023
Changing of the Guard: MSMR’s Second Editor-in-Chief Retires

Retrospective of Dr. Francis L. O’Donnell’s 11-year tenure as MSMR’s Editor in Chief

Brief Report: Hospitalizations Among Active Duty Members of the U.S. Coast Guard, Fiscal Year 2021

Article
2/1/2023
HospitalizationsCoastGuard

This brief report presents United States Coast Guard hospitalization data for fiscal year 2021 and examines its data completeness, as annual Department of Defense data have not included Coast Guard data since 2015, and describes differences in utilization.

From the Editor's Desk

Article
2/1/2023
From the Editor's Desk

The new MSMR Editor-in-Chief, Dr. Andrew Wiesen, a retired Army physician, provides his perspective on the importance of the MSMR and his expectations for its future.

Historical Perspective: The Critical Role of Disease and Non-Battle Injuries in Soldiers Isolated on Pacific Islands During the Second World War

Article
2/1/2023
SoldiersPacificWWII

This Historical Perspective discusses catastrophic casualties among U.S. and Japanese forces due to failed supply lines during World War II in the Pacific.

MSMR Vol. 30 No. 1 - January 2023

Report
1/1/2023

A monthly publication of the Armed Forces Health Surveillance Division. This issue of the peer-reviewed journal contains the following articles: Incidence and management of chronic insomnia, active component, U.S. Armed Forces, 2012 to 2021; Changes in the prevalence of overweight and obesity and in the incidence of prediabetes and type 2 diabetes during the COVID-19 pandemic, active component service members, U.S. Armed Forces, 2018 to 2021; Trends in the incidence of eating disorders among active component service members, 2017 to 2021.

Incidence and Management of Chronic Insomnia, Active Component, U.S. Armed Forces, 2012 to 2021

Article
1/1/2023
Incidence and Management of Chronic Insomnia, Active Component, U.S. Armed Forces, 2012 to 2021

Incidence and Management of Chronic Insomnia, Active Component, U.S. Armed Forces, 2012 to 2021.

Increased Prevalence of Overweight and Obesity and Incidence of Prediabetes and Type 2 Diabetes During the COVID-19 Pandemic, Active Component Service Members, U.S. Armed Forces, 2018 to 2021

Article
1/1/2023
Trends in the incidence of eating disorders among active component service members, 2017 to 2021.

Increased Prevalence of Overweight and Obesity and Incidence of Prediabetes and Type 2 Diabetes During the COVID-19 Pandemic, Active Component Service Members, U.S. Armed Forces, 2018 to 2021.

Trends in the Incidence of Eating Disorders Among Active Component Service Members, 2017 to 2021

Article
1/1/2023
Changes in the prevalence of overweight and obesity and in the incidence of prediabetes and type 2 diabetes during the COVID-19 pandemic, active component service members, U.S. Armed Forces, 2018 to 2021.

Trends in the Incidence of Eating Disorders Among Active Component Service Members, 2017 to 2021.

MSMR Vol. 29 No. 12 - December 2022

Report
12/1/2022

A monthly publication of the Armed Forces Health Surveillance Division. This issue of the peer-reviewed journal contains the following articles: Surveillance trends for SARS-CoV-2 and other respiratory pathogens among U.S. Military Health System Beneficiaries, Sept. 27, 2020 – Oct. 2,2021; Establishment of SARS-CoV-2 genomic surveillance within the MHS during March 1 – Dec. 31 2020; Suicide behavior among heterosexual, lesbian/gay, and bisexual active component service members in the U.S. Armed Forces; Brief report: Phase I results using the Virtual Pooled Registry Cancer Linkage system (VPR-CLS) for military cancer surveillance.

Seroepidemiologic Investigation of a COVID-19 Outbreak Aboard a U.S. Navy Ship

Article
12/1/2022
Cover 1

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus, the cause of coronavirus disease 2019 (COVID-19), has been responsible for the largest respiratory illness pandemic since the influenza pandemic of 1918.

Page 1 of 15 , showing items 1 - 15
First < 1 2 3 4 5  ... > Last 
Refine your search
Last Updated: October 24, 2022
Follow us on Instagram Follow us on LinkedIn Follow us on Facebook Follow us on Twitter Follow us on YouTube Sign up on GovDelivery